SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (656)4/28/1998 8:24:00 AM
From: crysball  Read Replies (1) | Respond to of 1491
 
Concur that Cataract Post-Op is the current market for Lotemax, but what will the marketplace look like in a few years, when the cost and time for vision correction surgery [PTK -Sands procedure et al] have dropped significantly, and the Post-Op vision correction market may far exceed the Cataract Pot-Op?

David, would you share with us your reasoning on raising your 18 month target for PARS to $15 share?

Could you also advise your impressions of Pars Israel?



To: David Israel-Rosen who wrote (656)4/29/1998 1:09:00 PM
From: Rick Strange  Read Replies (2) | Respond to of 1491
 
David,
Do you have any idea who BOL will select to co-market Alrex to the General Practice and Allergy Professionals? Seems to me that they would want that arrangement in place prior to the June 1st. roll-out.



To: David Israel-Rosen who wrote (656)5/1/1998 4:12:00 PM
From: crysball  Read Replies (1) | Respond to of 1491
 
Excellent bottom fishing at the close today.



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News